Cambridge, UK, 6th December 2017 / Domainex Ltd, a privately-owned drug discovery services company, is pleased to announce that Chris Brown has been appointed Chief Financial Officer with immediate effect.
6th December 2017
12th September 2017
Cambridge, UK and Stevenage, UK – 12 September 2017 - Domainex and Auspherix have announced new data from their collaboration to develop novel candidate drugs to tackle the
14th June 2017
Cambridge, UK, 14 June 2017/ Domainex Ltd.
17th May 2017
Domainex signs multi-year agreement with Dotmatics – a leading provider of scientific informatics – to streamline its integrated drug discovery services
30th March 2017
Domainex, a drug discovery services company, is pleased to announce that Dr Timo Veromaa has been appointed Executive Chairman with immediate effect.
7th March 2017
Domainex launched its fragment screening service, FragmentBuilder, and is the first CRO in the UK to offer MicroScale Thermophoresis (MST) as part of drug discovery services.
15th December 2016
Domainex has purchased a Monolith NT. Automated instrument, using MicroScale Thermophoresis (MST) technology for high-throughput fragment-based drug discovery.
17th November 2016
Sir Simon Campbell opened the Domainex Medicines Research Centre, which will double the laboratory space available to the company’s growing team of scientists.
12th September 2016
To support the company’s growth in drug research services, Domainex is moving to the Churchill Building of Chesterford Research Park.
26th April 2016
Queen’s University Belfast and Domainex Ltd secure funding from the Wellcome Trust to accelerate early development of first-in-class FLIP inhibitors.